John R. van Nagell Jr., MD

Director, Ovarian Cancer Screening Program

Clinical interests

  • Gynecologic Cancer
  • Ovarian Cancer Screening
  • Ovarian Cancer

John R. van Nagell Jr., MD

Director, Ovarian Cancer Screening Program


My name is John R. van Nagell; I received my medical degree from the University of Pennsylvania, School of Medicine, Philadelphia. I then completed a fellowship at the University of Kentucky, Lexington.

I am board certified by the American Board of Obstetrics and Gynecology in Gynecologic Oncology. I am an American Cancer Society Professor of Clinical Oncology, and am the past president of the Society of Gynecologic Oncology.

Faculty rank

Professor of Obstetrics and Gynecology


University of Pennsylvania, School of Medicine, Philadelphia

University of Kentucky, Lexington

University of Kentucky, Lexington

Certifications or Special training
American Board of Obstetrics and Gynecology
American Board of Obstetrics and Gynecology, Gynecologic Oncology

Gynecologic Oncology

Gynecologic Oncology Clinic

Markey Cancer Center
Whitney-Hendrickson Building
Third Floor, Room 330A
740 Rose St.
Lexington KY 40536-0098

Call 859-323-5553
Call 866-340-4488
Fax 859-323-1602

Directions to Markey Cancer Center - Whitney-Hendrickson Building »

UK HealthCare accepts many forms of insurance. See list of insurers »

  1. Lefringhouse JR, Neward E, Ueland FR, Baldwin LA, Miller RW, DeSimone CP, Kryscio RJ, van Nagell JR, Pavlik EJ. Probability of fallopian tube and ovarian detection with transvaginal ultrasonography in normal women. Womens Health (Lond). 2016 Jun;12(3):303-11.
    View in: PubMed
  2. van Nagell JR, Miller RW. Evaluation and Management of Ultrasonographically Detected Ovarian Tumors in Asymptomatic Women. Obstet Gynecol. 2016 May;127(5):848-58.
    View in: PubMed
  3. Ormsby EL, Pavlik EJ, van Nagell JR. Ultrasound follow up of an adnexal mass has the potential to save lives. Am J Obstet Gynecol. 2015 Nov;213(5):657-61, 657.e1.
    View in: PubMed
  4. Baldwin LA, Hoff JT, Lefringhouse J, Zhang M, Jia C, Liu Z, Erfani S, Jin H, Xu M, She QB, van Nagell JR, Wang C, Chen L, Plattner R, Kaetzel DM, Luo J, Lu M, West D, Liu C, Ueland FR, Drapkin R, Zhou BP, Yang XH. CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling. Oncotarget. 2014 Dec 15;5(23):12203-17.
    View in: PubMed
  5. Elder JW, Pavlik EJ, Long A, Miller RW, DeSimone CP, Hoff JT, Ueland WR, Kryscio RJ, van Nagell JR, Ueland FR. Serial ultrasonographic evaluation of ovarian abnormalities with a morphology index. Gynecol Oncol. 2014 Oct;135(1):8-12.
    View in: PubMed
  6. Maruyama Y, VanNagell JR, Yoneda J, Donaldson E, Gallion H, Rowley K, Kryscio R, Beach JL. Phase I-II clinical trial of Californium-252. Treatment of stage IB carcinoma of the cervix. Cancer. 1987 Apr 15; 59(8):1500-5. PMID: 3028603.
    View in: PubMed
  7. Kamath CR, Maruyama Y, DeLand FH, vanNagell JR. Value of bone scanning in detecting occult skeletal metastases from adenocarcinoma of the endometrium. Diagn Gynecol Obstet. 1982; 4(2):155-8. PMID: 7094822.
    View in: PubMed
  8. VanNagell J, Koepke J, Dilts PV. Preventable anemia and pregnancy. Obstet Gynecol Surv. 1971 Aug; 26(8):551-63. PMID: 5173747.
    View in: PubMed